Sana Biotechnology (NASDAQ:SANA) Upgraded to Buy at TD Cowen

Sana Biotechnology (NASDAQ:SANA) was upgraded by investment analysts at TD Cowen from a “hold” rating to a “buy” rating in a report released on Wednesday, MarketBeat Ratings reports.

SANA has been the subject of several other reports. HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of Sana Biotechnology in a report on Wednesday, November 27th. JMP Securities downgraded shares of Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, November 5th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Sana Biotechnology has an average rating of “Moderate Buy” and an average target price of $14.25.

Sana Biotechnology Price Performance

SANA opened at $4.30 on Wednesday. The stock has a market capitalization of $960.06 million, a P/E ratio of -3.07 and a beta of 1.45. The company’s 50 day simple moving average is $2.40 and its 200-day simple moving average is $4.07. Sana Biotechnology has a one year low of $1.52 and a one year high of $12.00.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings data on Friday, November 8th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.01. As a group, analysts anticipate that Sana Biotechnology will post -1.16 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. FMR LLC raised its holdings in Sana Biotechnology by 16.3% in the third quarter. FMR LLC now owns 31,609,175 shares of the company’s stock worth $131,494,000 after purchasing an additional 4,438,949 shares during the period. Geode Capital Management LLC raised its stake in Sana Biotechnology by 9.6% during the 3rd quarter. Geode Capital Management LLC now owns 3,166,480 shares of the company’s stock worth $13,175,000 after buying an additional 276,055 shares during the period. State Street Corp lifted its holdings in Sana Biotechnology by 4.2% during the third quarter. State Street Corp now owns 6,627,320 shares of the company’s stock worth $27,570,000 after acquiring an additional 269,274 shares in the last quarter. Integral Health Asset Management LLC grew its stake in Sana Biotechnology by 22.4% in the second quarter. Integral Health Asset Management LLC now owns 1,200,000 shares of the company’s stock valued at $6,552,000 after acquiring an additional 220,000 shares during the period. Finally, Barclays PLC increased its holdings in shares of Sana Biotechnology by 126.6% in the third quarter. Barclays PLC now owns 318,910 shares of the company’s stock worth $1,325,000 after acquiring an additional 178,179 shares in the last quarter. Institutional investors and hedge funds own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.